There is "little, if any, clinical reason" to use angiotensin-converting enzyme (ACE) inhibitors for the treatment of hypertension or other cardiovascular indications because angiotensin receptor ...

Angiotensin-converting enzyme (ACE) inhibitors are the mainstay of therapy for patients with systemic sclerosis in scleroderma renal crisis, however mortality remains high even in the post-ACE ...

Angiotensin-converting–enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) are recommended widely as first-line treatments for hypertension in patients with diabetic or nondiabetic ...

In a patient on an ACE inhibitor, how do you monitor serum creatinine, especially when it’s starting to rise? Do you ever stop the ACE inhibitor and change to another BP medication? How does the ...

Since the introduction of ARBs, the question that has pervaded each clinician’s mind is whether or not these drugs serve an advantage in conditions long addressed by ACE inhibitors. Matchar et al ...

Stopping renin-angiotensin-aldosterone inhibitors after hyperkalemia may offset their potential clinical benefits, according to investigators. Continuation of angiotensin-converting enzyme (ACE) ...

Angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and angiotensin receptor neprilysin inhibitors (ARNIs) can treat systolic heart failure. A doctor may also suggest ...

Please provide your email address to receive an email when new articles are posted on . There was a significant independent link between angiotensin-converting enzyme inhibitor use and all-cause ...

The blood pressure medication enalapril did not prevent cardiotoxicity among patients with cancer being treated with chemotherapy. The angiotensin-converting enzyme (ACE) inhibitor enalapril, a common ...

Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels, a ...

The free hormone hypothesis: Correlation of decreases in PSA with free testosterone rather than total testosterone in men with advanced prostate cancer treated with GTx-758. Use of supportive measures ...